Trial NCT04421378

View at ClinicalTrials.gov 
Org. Study IDs: XPORT-GBM-029
Secondary IDs: 2021-000080-67

Last trial update was posted on 2023-09-06

MeSH Interventions

Bevacizumab Carmustine Lomustine Temozolomide

MeSH Conditions

Glioblastoma

Other Conditions

Glioblastoma Multiforme

Stopping Reasons

Upon further consideration of the existing data and the competitive landscape, Karyopharm Therapeutics Inc has decided not to pursue the ongoing development of Selinexor in GBM at this time.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID